Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term aa [Analogs & Derivatives]. Found 14 abstracts

Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Molecular Pharmacology. 2005 Feb;67(2):545-57.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Molecular Pharmacology. 2004 May;65(5):1070-9.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Chen ZJ, Gate L, Davis W, Ile KE, Tew KD. Sensitivity and fidelity of DNA microarray improved withintegration of Amplified Differential Gene Expression (ADGE). BMC Genomics. 2003 Jul 14;4(1):28.
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer. 2003 Jan;34(2-3):121-8.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term aa [Analogs & Derivatives]

aa [Analogs & Derivatives] me [Metabolism] dt [Drug Therapy] pd [Pharmacology] Female Antineoplastic Combined Chemotherapy Protocols de [Drug Effects] ad [Administration & Dosage] Male pa [Pathology] 951-77-9 (Deoxycytidine) [Therapeutic Use] tu [Therapeutic Use] tu Deoxycytidine 0 (Antineoplastic Combined Chemotherapy Protocols) Fluorouracil Ovarian Neoplasms 80 and over Aged Camptothecin rt [Radiotherapy] Non-US Gov't Research Support 51-21-8 (Fluorouracil) Antineoplastic Agents 7689-03-4 (Camptothecin) Middle Aged Survival Analysis ch [Chemistry] bi [Biosynthesis] 103882-84-4 (gemcitabine) ph [Physiology] Adult Cell Division 0 (Antineoplastic Agents) Isoenzymes ai [Antagonists & Inhibitors] Comparative Study Aged Phenotype Human en [Enzymology] sc [Secondary] Use] Enzymologic Gene Expression Regulation Rats su [Surgery] Neoplasm Staging Phytogenic) 0 (Antineoplastic Agents 100286-90-6 (irinotecan) tu [Therapeutic Cultured Tumor Cells Antineoplastic) 0 (Antimetabolites 72025-60-6 (Leukotriene C4) Antitumor Drug Screening Assays 85622-93-1 (temozolomide) Tumor Cell Line Biological Tumor Markers Lung Neoplasms Leukotriene C4 Multiple Drug Resistance st [Standards] Neoplasm Proteins SCID Mice Predictive Value of Tests ci [Chemically Induced] 0 (Isoenzymes) ge [Genetics] Antineoplastic Antimetabolites Biological) 0 (Tumor Markers Phytogenic Antineoplastic Agents 0 (Neoplasm Proteins) Cell Cycle Non-US Gov't Support Drug Dose-Response Relationship Reverse Transcriptase Polymerase Chain Reaction Adjuvant Radiotherapy 4342-03-4 (Dacarbazine) Dacarbazine Proportional Hazards Models Neoplastic Gene Expression Regulation Mice EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Cisplatin Azo Compounds Neoplasm) 0 (DNA p38 Mitogen-Activated Protein Kinases 0 (ATP-Binding Cassette Transporters) LLC-PK1 Cells 0 (Transcription Factor AP-1) Xenograft Model Antitumor Assays 0 (Anticarcinogenic Agents) Colorectal Neoplasms Transcription Factor AP-1 Protein Kinases Transcription Factors Survival Rate 33419-42-0 (Etoposide) 10102-43-9 (Nitric Oxide) ri [Radionuclide Imaging] erbB-2) EC 2-7-1-112 (Receptor 3T3 Cells human) 0 (ABCC11 protein 0 (Prodrugs) 0 (Enzyme Inhibitors) Vascular Endothelial Growth Factor A mo [Mortality] 2-diamine (N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1 Protein p53 169590-42-5 (celecoxib) Prodrugs 0 (Sesquiterpenes) 4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl 0 (O(2)-(2 Gene Expression Profiling Logistic Models 0 (Vascular Endothelial Growth Factor A) Radioimmunotherapy 684-93-5 (Methylnitrosourea) 4-Aminobenzoic Acid EC 2-1-1-45 (Thymidylate Synthase) Vitamin E Glutathione Transferase Cytotoxins Cytoplasmic and Nuclear Receptors 33069-62-4 (Paclitaxel) Vindesine 23214-92-8 (Doxorubicin) Disease-Free Survival im [Immunology] pk Renal Cell Carcinoma 0 (Folfox protocol) 0 (Cyclins) 1406-18-4 (Vitamin E) 0 (Sulfonamides) 0 (Taxoids) Cytoplasmic and Nuclear) 0 (Receptors Enzyme Activation Alkylating) 0 (Antineoplastic Agents Neoadjuvant Therapy 0 (DNA-Binding Proteins) Small Cell Carcinoma Glioma EC 2-7-1 (mTOR protein) EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) 0 (Organoplatinum Compounds) Topotecan EC 2-5-1-18 (glutathione S-transferase pi) Organoplatinum Compounds 0 (Immunotoxins) erbB-2 Receptor
Last updated on Wednesday, February 05, 2020